Literature DB >> 2200754

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules.

S Binet1, E Chaineau, A Fellous, H Lataste, A Krikorian, J P Couzinier, V Meininger.   

Abstract

Among the various non-naturally-occurring Vinca alkaloid compounds, nor-anhydro-vinblastine (Navelbine, NVB) exhibits in preliminary clinical studies broader anti-tumor activity and lower neurotoxicity than vinblastine (VBL) and vincristine (VCR). The action of these 3 Vinca alkaloids on axonal and mitotic microtubules has been studied experimentally in a specific model, the tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation. Post-implantation embryos were cultured in toto in a medium containing increasing concentrations of drugs. Microtubules were stained using immunofluorescence with a tubulin-specific polyclonal antibody in semi-thin sections after embedding in high-molecular-weight polyethylene glycol. All drugs induced depolymerization of mitotic interpolar microtubules and cell metaphase block at the same concentration. Increasing the concentrations led to progressive depolymerization of kinetochore microtubules. However, NVB was the only drug to induce complete microtubule depolymerization. The activity of the 3 compounds on axonal microtubules was identical: depolymerization of a labile pool of microtubules. This was observed at higher concentrations with NVB than with the 2 other Vinca alkaloids. Our results show that, in this model, NVB is as active on mitotic microtubules as VCR and VBL, and less active on axonal microtubules. None of the 3 drugs modified microtubule length but all appeared to induce disruption of the labile microtubule pool without altering the stable pool.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200754     DOI: 10.1002/ijc.2910460220

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

Review 1.  Interphase microtubules: chief casualties in the war on cancer?

Authors:  Angela Ogden; Padmashree C G Rida; Michelle D Reid; Ritu Aneja
Journal:  Drug Discov Today       Date:  2013-11-04       Impact factor: 7.851

2.  Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.

Authors:  Peter Schmid; Volker Heilmann; Carsten-Oliver Schulz; Annette Dieing; Silvia Lehenbauer-Dehm; Christian Jehn; Orhan Sezer; Kurt Possinger; Bernd Flath
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 3.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.

Authors:  Laurent Nguyen; Brigitte Tranchand; Christian Puozzo; Philippe Variol
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

Review 6.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 7.  PXR: More Than Just a Master Xenobiotic Receptor.

Authors:  Peter O Oladimeji; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2017-11-07       Impact factor: 4.436

8.  Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.

Authors:  John F Kuttesch; Mark D Krailo; Timothy Madden; Mary Johansen; Archie Bleyer
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

Review 9.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat.

Authors:  K D Tanner; D B Reichling; J D Levine
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.